Sagimet Biosciences (NASDAQ:SGMT) announced 52-week results from license partner Ascletis’ Phase 3 open-label extension trial of denifanstat in moderate to severe acne, with treatment success reaching 56.7% among 240 patients.
AbbVie (NYSE:ABBV) announced Phase 1 results for investigational ABBV-295, reporting adjusted mean weight reductions of up to 9.8% after 12 weeks of weekly dosing in a study involving 60 participants.
Takeda (NYSE:TAK) announced Phase 3 LATITUDE study results for investigational drug zasocitinib (TAK-279), reporting statistically significant improvements compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis.
AbbVie (NYSE:ABBV) announced that it will present 60 dermatology research abstracts, including three late-breaking presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, covering multiple immune-mediated skin diseases.
AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.
Oncolytics Biotech (NASDAQ:ONCY) reported published preclinical findings showing that pelareorep increased markers associated with immune activation in hepatocellular carcinoma (HCC), the most common form of liver cancer.
Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue exceeding $15 million at its CosmoFarm pharmacy distribution subsidiary.
Propanc Biopharma (NASDAQ:PPCB) reported fiscal 2026 financial results and provided an update on development plans for PRP, its investigational cancer therapy candidate.
Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 revenue guidance following stronger-than-expected demand for its commercial products, Amtagvi and Proleukin.
Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.
BeyondSpring (NASDAQ:BYSI) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Plinabulin in combination with docetaxel for previously treated advanced non-squamous lung cancer.
Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.
